Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Multicenter, phase III Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan (BR-A-657-K) 30mg Compared to Placebo in Patients with Mild to Moderate Essential Hypertension

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Multicenter, phase III Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan (BR-A-657-K) 30mg Compared to Placebo in Patients with Mild to Moderate Essential Hypertension

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fimasartan (Primary) ; Valsartan
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Boryung

    • Most Recent Events

    • 30 Jun 2016 Status changed from recruiting to completed.
    • 24 Aug 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01672476).
    • 24 Aug 2012 Planned End Date 1 Mar 2013 added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top